STOCK (NASDAQ:TPPH)
0.00 (
N/A
)
3:19pm Mountain Time
 NASDAQ InfoQuotes
Stock Quote
(NASDAQ.COM)
LATEST PRESS RELEASES
Tapestry Receives Notice Regarding Minimum Bid Price Rule
December 21, 2007
Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors
December 5, 2007
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data from its Phase 2 Prostate Cancer Trial
November 5, 2007
MEDIA COVERAGE
2006 ANNUAL REPORT
CONTACT INFORMATION
Gordon Link
SVP, CFO
4840 Pearl East Circle, #300W
Boulder, CO 80301
Tel 303 516 8500 ext 503
E-mail: glink@tapestrypharma.com
|
Tapestry Pharmaceuticals, Inc. is a company focused on developing proprietary therapies for
the treatment of cancer. We are also actively engaged in evaluating new therapeutic agents
and related technologies for in-licensing.
Tapestry's technical expertise is our ability to identify, chemically alter and produce
novel therapeutic compounds derived from natural product sources.
Tapestry has developed a novel third generation taxane, TPI 287. In December 2004 we filed
an IND application, and on January 21, 2005, we were cleared to proceed with clinical trials
by the FDA. In May, 2005 our first TPI 287 Phase I study began.
|
|
|
